| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
NCT01842113: Quality of Life and Nutritional Improvements in Cirrhotic Patients |
|
|
| Terminated | 4 | 4 | US | Rifaximin, Xifaxan, Lactulose, Enulose, Generlac, Cholac, Constulose, Kristalose, Laxilose, Portalac, Hepatalac, Constilac, Lactulose Placebo, Rifaximin Placebo, Sugar Pill | Tampa General Hospital | Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension | 05/14 | | | |
NCT01842581: The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy |
|
|
| Completed | 4 | 222 | US | Rifaximin, Xifaxan®, Lactulose | Bausch Health Americas, Inc. | Hepatic Encephalopathy, Cirrhosis | 12/14 | 12/14 | | |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
NCT02158182: Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding |
|
|
| Completed | 4 | 88 | RoW | Lactulose, L-ornithine L-aspartate, Rifaximin, Placebo | Hospital General de Mexico | Hepatic Encephalopathy | 06/16 | 06/16 | | |
| Completed | 4 | 38 | Europe | Rifaximin-α, Targaxan (brand name), Placebo Oral Tablet | King's College Hospital NHS Trust, King's College London | Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive | 06/16 | 10/16 | | |
NCT04736836: Microbial Resistance of Rifaximin in Hepatic Encephalopathy |
|
|
| Completed | 4 | 100 | NA | Rifaximin | National Hepatology & Tropical Medicine Research Institute | Hepatic Encephalopathy | 12/18 | 06/19 | | |
2018-004323-37: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-centre randomized, double blind, placebo controlled trial. The PEARL trial |
|
|
| Not yet recruiting | 4 | 238 | Europe | Xifaxan, Lactulose, Tablet, Syrup, Xifaxan, Lactulose | Academic Medical Centre, Academic Medical Centre, ZonMw, Norgine B.V. | post-TIPS Hepatic Encephalopathy (HE), Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt placement, Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT03077217: Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy |
|
|
| Completed | 4 | 40 | RoW | Rifaximin | Shanghai Changzheng Hospital | Covert Hepatic Encephalopathy | 05/20 | 05/20 | | |
PEARL, NCT04073290: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose |
|
|
| Recruiting | 4 | 238 | Europe | Rifaximin 550 milligram Oral Tablet [XIFAXAN], TARGAXAN, Placebo oral tablet, Placebo, Lactulose 667 milligram/milliliter Oral Solution, Lactulose syrup | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen Leuven, Norgine | Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases, Pathological Processes | 09/22 | 09/23 | | |
